Aptamers as therapeutics in cardiovascular diseases

Current Medicinal Chemistry

Volumn 18, Issue 27, 2011, Pages 4169-4174

  Wang, P ^a   Yang, Y ^b   Hong, H ^b   Zhang, Y ^b   Cai, W ^b,c   Fang, D ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Aptamers; Cardiovascular diseases; DNA; Factor IX; Peptide aptamer; RNA; Thrombin; Von Willebrand factor (vWF)

Indexed keywords

APTAMER; ARC 1172; BLOOD CLOTTING FACTOR 9; EGAPTIVON PEGOL; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTEGRIN; INTEGRIN ALPHA V BETA 3; PADGEM PROTEIN; PHOSPHOLAMBAN; PLATELET DERIVED GROWTH FACTOR; RB 006; RB 007; THROMBIN; UNCLASSIFIED DRUG; VASOPRESSIN; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; BINDING AFFINITY; BRAIN ISCHEMIA; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; EX VIVO STUDY; HUMAN; ISCHEMIC HEART DISEASE; MOLECULARLY TARGETED THERAPY; PATIENT CARE; REVIEW; VENOUS THROMBOEMBOLISM;

APTAMERS, NUCLEOTIDE; CARDIOVASCULAR DISEASES; FACTOR IX; HUMANS; MOLECULAR TARGETED THERAPY; THROMBIN; VON WILLEBRAND FACTOR;

EID: 80052244344     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797189673     Document Type: Review

References (77)

1. Ellington, A.D.; Szostak, J.W. In vitro selection of RNA molecules that bind specific ligands. Nature, 1990, 346, 818-822.
2. Tuerk, C.; Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 1990, 249, 505-510.
3. Keefe, A.D.; Pai, S.; Ellington, A. Aptamers as therapeutics. Nat. Rev. Drug Discov., 2010, 9, 537-550.
4. Gold, L.; Janjic, N.; Jarvis, T.; Schneider, D.; Walker, J.J.; Wilcox, S.K.; Zichi, D. Aptamers and the RNA World, Past and Present. Cold Spring Harb. Perspect. Biol., 2010, Epub.
5. Thiel, K.W.; Giangrande, P.H. Therapeutic applications of DNA and RNA aptamers. Oligonucleotides, 2009, 19, 209-222.
6. Fang, X.; Tan, W. Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc. Chem. Res., 2010, 43, 48-57.
7. Mayer, G. The chemical biology of aptamers. Angew. Chem. Int. Ed. Engl., 2009, 48, 2672-2689.
8. Lin, Y.; Nieuwlandt, D.; Magallanez, A.; Feistner, B.; Jayasena, S.D. Highaffinity and specific recognition of human thyroid stimulating hormone (hTSH) by in vitro-selected 2′-amino-modified RNA. Nucleic Acids Res., 1996, 24, 3407-3414. (Pubitemid 26294453)
9. Rusconi, C.P.; Scardino, E.; Layzer, J.; Pitoc, G.A.; Ortel, T.L.; Monroe, D.; Sullenger, B.A. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature, 2002, 419, 90-94. (Pubitemid 34987876)
10. Pagratis, N.C.; Bell, C.; Chang, Y.F.; Jennings, S.; Fitzwater, T.; Jellinek, D.; Dang, C. Potent 2′-amino-, and 2′-fluoro-2′- deoxyribonucleotide RNA inhibitors of keratinocyte growth factor. Nat. Biotechnol., 1997, 15, 68-73.
11. King, D.J.; Safar, J.G.; Legname, G.; Prusiner, S.B. Thioaptamer interactions with prion proteins: sequence-specific and non-specific binding sites. J. Mol. Biol., 2007, 369, 1001-1014. (Pubitemid 46754057)
12. Takafuji, Y.; Jo, J.I.; Tabata, Y. Simple PEG Modification of DNA Aptamer Based on Copper Ion Coordination for Tumor Targeting. J. Biomater. Sci. Polym. Ed., 2010, Epub.
13. Eulberg, D.; Klussmann, S. Spiegelmers: biostable aptamers. Chembiochem, 2003, 4, 979-983. (Pubitemid 37267585)
14. Vater, A.; Klussmann, S. Toward third-generation aptamers: Spiegelmers and their therapeutic prospects. Curr. Opin. Drug Discov. Devel., 2003, 6, 253-261. (Pubitemid 36368380)
15. Borghouts, C.; Kunz, C.; Groner, B. Peptide aptamers: recent developments for cancer therapy. Expert Opin. Biol. Ther., 2005, 5, 783-797. (Pubitemid 40873887)
16. Hoppe-Seyler, F.; Crnkovic-Mertens, I.; Tomai, E.; Butz, K. Peptide aptamers: specific inhibitors of protein function. Curr. Mol. Med., 2004, 4, 529-538. (Pubitemid 38961196)
17. Colas, P.; Cohen, B.; Jessen, T.; Grishina, I.; McCoy, J.; Brent, R. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature, 1996, 380, 548-550. (Pubitemid 26110646)
18. Liss, M.; Petersen, B.; Wolf, H.; Prohaska, E. An aptamer-based quartz crystal protein biosensor. Anal. Chem., 2002, 74, 4488-4495. (Pubitemid 35006438)
19. Ng, E.W.; Shima, D.T.; Calias, P.; Cunningham, E.T., Jr.; Guyer, D.R.; Adamis, A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov., 2006, 5, 123-132.
20. Keefe, A.D.; Schaub, R.G. Aptamers as candidate therapeutics for cardiovascular indications. Curr. Opin. Pharmacol., 2008, 8, 147-152.
21. Kuliczkowski, W.; Floyd, J.; Malinin, A.; Serebruany, V. Aptamers: the emerging class of future anticoagulation for vascular disease. Expert Rev. Cardiovasc. Ther., 2010, 8, 503-507.
22. White, R.R.; Sullenger, B.A.; Rusconi, C.P. Developing aptamers into therapeutics. J. Clin. Invest., 2000, 106, 929-934.
23. Becker, R.C.; Oney, S.; Becker, K.C.; Rusconi, C.P.; Sullenger, B. Nucleic acid aptamers and their complimentary antidotes. Entering an era of antithrombotic pharmacobiologic therapy. Hamostaseologie, 2007, 27, 378-382.
24. Sadler, J.E. Biochemistry and genetics of von Willebrand factor. Annu. Rev. Biochem., 1998, 67, 395-424. (Pubitemid 28411134)
25. Moake, J.L.; Chow, T.W. Increased von Willebrand factor (vWf) binding to platelets associated with impaired vWf breakdown in thrombotic thrombocytopenic purpura. J. Clin. Apher., 1998, 13, 126-132. (Pubitemid 28507004)
26. Lip, G.Y.; Blann, A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc. Res., 1997, 34, 255-265. (Pubitemid 27241568)
27. Paulinska, P.; Spiel, A.; Jilma, B. Role of von Willebrand factor in vascular disease. Hamostaseologie, 2009, 29, 32-38.
28. Gilbert, J.C.; DeFeo-Fraulini, T.; Hutabarat, R.M.; Horvath, C.J.; Merlino, P.G.; Marsh, H.N.; Healy, J.M.; Boufakhreddine, S.; Holohan, T.V.; Schaub, R.G. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation, 2007, 116, 2678-2686. (Pubitemid 350291240)
29. Spiel, A.O.; Mayr, F.B.; Ladani, N.; Wagner, P.G.; Schaub, R.G.; Gilbert, J.C.; Jilma, B. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction. Platelets, 2009, 20, 334-340.
30. Diener, J.L.; Daniel Lagasse, H.A.; Duerschmied, D.; Merhi, Y.; Tanguay, J.F.; Hutabarat, R.; Gilbert, J.; Wagner, D.D.; Schaub, R. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the antivon Willebrand factor A1-domain aptamer ARC1779. J. Thromb. Haemost., 2009, 7, 1155-1162.
31. Arzamendi, D.; Dandachli, F.; Theoret, J.F.; Ducrocq, G.; Chan, M.; Mourad, W.; Gilbert, J.G.; Schaub, R.G.; Tanguay, J.F.; Merhi, Y. An Antivon Willebrand Factor Aptamer Reduces Platelet Adhesion Among Patients Receiving Aspirin and Clopidogrel in an Ex Vivo Shear-Induced Arterial Thrombosis. Clin. Appl. Thromb. Hemost., 2010, Epub.
32. Gabriel, H.M.; Oliveira, E.I. Role of abciximab in the treatment of coronary artery disease. Expert Opin. Biol. Ther., 2006, 6, 935-942.
33. Chassot, P.G.; Delabays, A.; Ravussin, P.; Spahn, D.R. Antiplatelet drugs and intraoperative hemorrhage. Rev. Med. Suisse, 2006, 2, 2684-2687.
34. Jilma-Stohlawetz, P.; Gorczyca, M.E.; Jilma, B.; Siller-Matula, J.; Gilbert, J.C.; Knobl, P. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb. Haemost., 2011, 105, 545-552.
35. Knobl, P.; Jilma, B.; Gilbert, J.C.; Hutabarat, R.M.; Wagner, P.G.; Jilma-Stohlawetz, P. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 2181-2185.
36. Mayr, F.B.; Knobl, P.; Jilma, B.; Siller-Matula, J.M.; Wagner, P.G.; Schaub, R.G.; Gilbert, J.C.; Jilma-Stohlawetz, P. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion, 2010, 50, 1079-1087.
37. Jilma, B.; Paulinska, P.; Jilma-Stohlawetz, P.; Gilbert, J.C.; Hutabarat, R.; Knobl, P. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Thromb. Haemost., 2010, 104, 563-570.
38. Huang, R.H.; Fremont, D.H.; Diener, J.L.; Schaub, R.G.; Sadler, J.E. A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1. Structure, 2009, 17, 1476-1484.
39. Oney, S.; Nimjee, S.M.; Layzer, J.; Que-Gewirth, N.; Ginsburg, D.; Becker, R.C.; Arepally, G.; Sullenger, B.A. Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides, 2007, 17, 265-274. (Pubitemid 47463359)
40. Lancellotti, S.; De Cristofaro, R. Nucleotide-derived thrombin inhibitors: a new tool for an old issue. Cardiovasc. Hematol. Agents Med. Chem., 2009, 7, 19-28.
41. Huntington, J.A. Molecular recognition mechanisms of thrombin. J. Thromb. Haemost., 2005, 3, 1861-1872. (Pubitemid 41716573)
42. Becker, R.C.; Rusconi, C.; Sullenger, B. Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. Thromb. Haemost., 2005, 93, 1014-1020. (Pubitemid 40823502)
43. Cirino, G.; Severino, B. Thrombin receptors and their antagonists: an update on the patent literature. Expert Opin. Ther. Pat., 2010, 20, 875-884.
44. Leger, A.J.; Covic, L.; Kuliopulos, A. Protease-activated receptors in cardiovascular diseases. Circulation, 2006, 114, 1070-1077. (Pubitemid 44358884)
45. Bock, L.C.; Griffin, L.C.; Latham, J.A.; Vermaas, E.H.; Toole, J.J. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature, 1992, 355, 564-566.
46. Paborsky, L.R.; McCurdy, S.N.; Griffin, L.C.; Toole, J.J.; Leung, L.L. The single-stranded DNA aptamer-binding site of human thrombin. J. Biol. Chem., 1993, 268, 20808-20811. (Pubitemid 23292253)
47. DeAnda, A., Jr.; Coutre, S.E.; Moon, M.R.; Vial, C.M.; Griffin, L.C.; Law, V.S.; Komeda, M.; Leung, L.L.; Miller, D.C. Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. Ann. Thorac. Surg., 1994, 58, 344-350. (Pubitemid 24285100)
48. Leung, L.L. Application of combinatorial libraries and protein engineering to the discovery of novel anti-thrombotic drugs. Thromb. Haemost., 1995, 74, 373-376.
49. Macaya, R.F.; Schultze, P.; Smith, F.W.; Roe, J.A.; Feigon, J. Thrombinbinding DNA aptamer forms a unimolecular quadruplex structure in solution. Proc. Natl. Acad. Sci. USA, 1993, 90, 3745-3749. (Pubitemid 23111444)
50. Wang, K.Y.; McCurdy, S.; Shea, R.G.; Swaminathan, S.; Bolton, P.H. A DNA aptamer which binds to and inhibits thrombin exhibits a new structural motif for DNA. Biochemistry, 1993, 32, 1899-1904. (Pubitemid 23086037)
51. Pagano, B.; Martino, L.; Randazzo, A.; Giancola, C. Stability and binding properties of a modified thrombin binding aptamer. Biophys. J., 2008, 94, 562-569.
52. Mendelboum Raviv, S.; Horvath, A.; Aradi, J.; Bagoly, Z.; Fazakas, F.; Batta, Z.; Muszbek, L.; Harsfalvi, J. 4-thio-deoxyuridylate-modified thrombin aptamer and its inhibitory effect on fibrin clot formation, platelet aggregation and thrombus growth on subendothelial matrix. J. Thromb. Haemost., 2008, 6, 1764-1771.
53. Bini, A.; Minunni, M.; Tombelli, S.; Centi, S.; Mascini, M. Analytical performances of aptamer-based sensing for thrombin detection. Anal. Chem., 2007, 79, 3016-3019. (Pubitemid 46595661)
54. Lowe, G.D. Factor IX and thrombosis. Br. J. Haematol., 2001, 115, 507-513. (Pubitemid 34015639)
55. Smith, S.B.; Gailani, D. Update on the physiology and pathology of factor IX activation by factor XIa. Expert Rev. Hematol., 2008, 1, 87-98.
56. Schmidt, A.E.; Bajaj, S.P. Structure-function relationships in factor IX and factor IXa. Trends Cardiovasc. Med., 2003, 13, 39-45. (Pubitemid 36120548)
57. Nimjee, S.M.; Keys, J.R.; Pitoc, G.A.; Quick, G.; Rusconi, C.P.; Sullenger, B.A. A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol. Ther., 2006, 14, 408-415. (Pubitemid 44184966)
58. Dyke, C.K.; Steinhubl, S.R.; Kleiman, N.S.; Cannon, R.O.; Aberle, L.G.; Lin, M.; Myles, S.K.; Melloni, C.; Harrington, R.A.; Alexander, J.H.; Becker, R.C.; Rusconi, C.P. First-in-human experience of an antidotecontrolled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation, 2006, 114, 2490-2497. (Pubitemid 44901522)
59. Chan, M.Y.; Rusconi, C.P.; Alexander, J.H.; Tonkens, R.M.; Harrington, R.A.; Becker, R.C. A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. J. Thromb. Haemost., 2008, 6, 789-796. (Pubitemid 351524539)
60. Chan, M.Y.; Cohen, M.G.; Dyke, C.K.; Myles, S.K.; Aberle, L.G.; Lin, M.; Walder, J.; Steinhubl, S.R.; Gilchrist, I.C.; Kleiman, N.S.; Vorchheimer, D.A.; Chronos, N.; Melloni, C.; Alexander, J.H.; Harrington, R.A.; Tonkens, R.M.; Becker, R.C.; Rusconi, C.P. Phase 1b randomized study of antidotecontrolled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation, 2008, 117, 2865-2874. (Pubitemid 351787073)
61. Cohen, M.G.; Purdy, D.A.; Rossi, J.S.; Grinfeld, L.R.; Myles, S.K.; Aberle, L.H.; Greenbaum, A.B.; Fry, E.; Chan, M.Y.; Tonkens, R.M.; Zelenkofske, S.; Alexander, J.H.; Harrington, R.A.; Rusconi, C.P.; Becker, R.C. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation, 2010, 122, 614-622.
62. Becker, R.C.; Chan, M.Y. REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis. Curr. Opin. Mol. Ther., 2009, 11, 707-715.
63. Povsic, T.J.; Cohen, M.G.; Chan, M.Y.; Zelenkofske, S.L.; Wargin, W.A.; Harrington, R.A.; Alexander, J.H.; Rusconi, C.P.; Becker, R.C. Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial Design. J. Thromb. Thrombolysis., 2011, Epub.
64. Povsic, T.J.; Cohen, M.G.; Mehran, R.; Buller, C.E.; Bode, C.; Cornel, J.H.; Kasprzak, J.D.; Montalescot, G.; Joseph, D.; Wargin, W.A.; Rusconi, C.P.; Zelenkofske, S.L.; Becker, R.C.; Alexander, J.H. A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial. Am. Heart J., 2011, 161, 261-268.
65. Paul, D.; Samuel, S.M.; Maulik, N. Mesenchymal stem cell: present challenges and prospective cellular cardiomyoplasty approaches for myocardial regeneration. Antioxid. Redox. Signal, 2009, 11, 1841-1855.
66. Pittenger, M.F.; Martin, B.J. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ. Res., 2004, 95, 9-20. (Pubitemid 38931831)
67. Schafer, R.; Wiskirchen, J.; Guo, K.; Neumann, B.; Kehlbach, R.; Pintaske, J.; Voth, V.; Walker, T.; Scheule, A.M.; Greiner, T.O.; Hermanutz-Klein, U.; Claussen, C.D.; Northoff, H.; Ziemer, G.; Wendel, H.P. Aptamer-based isolation and subsequent imaging of mesenchymal stem cells in ischemic myocard by magnetic resonance imaging. Rofo, 2007, 179, 1009-1015. (Pubitemid 47596612)
68. Strahm, Y.; Flueckiger, A.; Billinger, M.; Meier, P.; Mettler, D.; Weisser, S.; Schaffner, T.; Hess, O. Endothelial-cell-binding aptamer for coating of intracoronary stents. J. Invasive. Cardiol., 2010, 22, 481-487.
69. Tanaka, Y.; Honda, T.; Matsuura, K.; Kimura, Y.; Inui, M. In vitro selection and characterization of DNA aptamers specific for phospholamban. J. Pharmacol. Exp. Ther., 2009, 329, 57-63.
70. Gutsaeva, D.R.; Parkerson, J.B.; Yerigenahally, S.D.; Kurz, J.C.; Schaub, R.G.; Ikuta, T.; Head, C.A. Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood, 2011, 117, 727-735.
71. Jenison, R.D.; Jennings, S.D.; Walker, D.W.; Bargatze, R.F.; Parma, D. Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion. Antisense Nucleic Acid Drug Dev., 1998, 8, 265-279. (Pubitemid 28446114)
72. Leppanen, O.; Janjic, N.; Carlsson, M.A.; Pietras, K.; Levin, M.; Vargeese, C.; Green, L.S.; Bergqvist, D.; Ostman, A.; Heldin, C.H. Intimal hyperplasia recurs after removal of PDGF-AB and -BB inhibition in the rat carotid artery injury model. Arterioscler. Thromb. Vasc. Biol., 2000, 20, E89-95.
73. 3 integrin with an RNA aptamer impairs endothelial cell growth and survival. Biochem. Biophys. Res. Commun., 2005, 338, 956-963. (Pubitemid 41597735)
74. Higashimoto, Y.; Yamagishi, S.; Nakamura, K.; Matsui, T.; Takeuchi, M.; Noguchi, M.; Inoue, H. In vitro selection of DNA aptamers that block toxic effects of AGE on cultured retinal pericytes. Microvasc. Res., 2007, 74, 65-69. (Pubitemid 46855792)
75. Marro, M.L.; Daniels, D.A.; McNamee, A.; Andrew, D.P.; Chapman, T.D.; Jiang, M.S.; Wu, Z.; Smith, J.L.; Patel, K.K.; Gearing, K.L. Identification of potent and selective RNA antagonists of the IFN-gamma-inducible CXCL10 chemokine. Biochemistry, 2005, 44, 8449-8460. (Pubitemid 40799925)
76. Williams, K.P.; Liu, X.H.; Schumacher, T.N.; Lin, H.Y.; Ausiello, D.A.; Kim, P.S.; Bartel, D.P. Bioactive and nuclease-resistant L-DNA ligand of vasopressin. Proc. Natl. Acad. Sci. USA, 1997, 94, 11285-11290. (Pubitemid 27450990)
77. Missailidis, S.; Hardy, A. Aptamers as inhibitors of target proteins. Expert Opin. Ther. Pat., 2009, 19, 1073-1082.